Startup profile · funding coverage
Ciitizen funding, valuation and investors
Patient-consented medical records platform for cancer and chronic care.
Keep track of Ciitizen
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$17M · January 2019
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$17M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
acquired
acquired
Investors in latest funding
Lead: Andreessen Horowitz
Overview
Ciitizen helped patients exercise HIPAA rights to collect and share medical records for cancer and chronic care — aggregating records for trials and research. a16z Bio led seed and a $17M Series A in 2019. Invitae acquired Ciitizen in September 2021 for approximately $325M in cash and stock.
Why Ciitizen is interesting
Ciitizen used HIPAA access rights to aggregate records for trials and research — a16z Bio led seed and Series A before Invitae's $325M acquisition.
Product & use cases
Patient-consented medical records platform using HIPAA access rights to aggregate records for research and care coordination.
- Cancer patient record aggregation for trials
- Chronic care record portability
- Research-grade patient data consented sharing
Key facts
- Acquired by Invitae (Sep 2021): ~$325M cash and stock (PR Newswire, MedCity News)
- Series A (Jan 2019): $17M led by a16z Bio; Section 32, Verily participated (TechCrunch)
- Source: https://www.prnewswire.com/news-releases/invitae-to-acquire-ciitizen-to-strengthen-its-patient-consented-health-data-platform-to-improve-personal-outcomes-and-global-research-301369974.html
Funding history (newest first)
Investors in our directory
Funds linked from Ciitizen's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Ciitizen differentiates through focused product scope and a16z-backed GTM in its category — see competitors for tradeoffs vs. incumbents.
Ciitizen operates in a competitive category where incumbents have distribution but startups win on workflow fit. See named competitors for honest better/worse notes; we do not invent market share.
-
Apple Health Records adjacent
Consumer health record aggregation; Ciitizen cancer/chronic focus.
-
Invitae direct
Acquirer; integrated Ciitizen into patient data platform.
Notable stories
- Acquired by Invitae (Sep 2021): ~$325M cash and stock (PR Newswire, MedCity News)
- Series A (Jan 2019): $17M led by a16z Bio; Section 32, Verily participated (TechCrunch)
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Ciitizen's financing or category context.
FAQs about Ciitizen
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.